Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
SAN DIEGO, Aug. 29, 2017 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will participate in a panel discussion entitled “Precision Medicine in Oncology and Next Generation Diagnostics” at Citi’s 12th Annual Biotech Conference, in Boston on September 6, 2017. The panel is scheduled to begin at 1:00 p.m. EDT (10:00 a.m. PDT).
A live audio webcast of the panel discussion will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
